InvestorsHub Logo
icon url

Carboat

08/22/15 9:02 PM

#231458 RE: pphmtoolong #231384

They stubbornly refuse to loosen their grasp on the IP pipeline. No sharing with a partner, no sharing with a lender, no sharing with anybody. Many not happy with this approach. Still stubbornly refusing to sell the IP cheaply despite the prospect of ATM dilution.


Have you considered they may have had no offers for bavi since the botced trial? And if they have gotten to the table since the trial shows that they are poor negotiators and could not put a deal together.
icon url

Protector

08/23/15 5:04 AM

#231475 RE: pphmtoolong #231384

pphmtoolong. I agree and well put.

The stubbornness at PPHM comes from King, backed by ES, he/they is/are determined. And King is surrounded by people like Dr. Garnick, Shan that know how to make it happen. And they have a great team of plenty of other people that believe in Bavituximab (Hutchins, Empig, ...).

It becomes each day easier for them to follow that path because it is a high risk path in the beginning if you have no idea if all intended plans and scientific theories will come through and it get undone of risk little by little over time as puzzle peace's get solved. For instance no creditors is good because no bankruptcy risk. Unencumbered pipelines and IP is good because all leverage to shareholders and hands-free negotiation power.

Those that have nothing go BC quite early if the market detects they are only wind. Those that have something often get in trouble because of funding and are picked up for breadcrumbs.

Others like Genetech make it further down the line on their own and have more to show for at the moment they get acquired and get more. they also negotiate from a stronger position.

Peregrine passed the "has nothing" phase and the science is no longer under dispute. With SUNRISE PPHM can officially set the record for bavituximabs performance after it was officially set to a VERY GODD 60% SOC improvement and non officially to 113+% SOC improvement due to the dose switching.

Avid II revenue will increase the companies strength and a first approval will put it in a financial secure place not depending on the ATM.

And all that indeed because the BoD stubbornly pushed its agenda for the good of the company, in the long term interest of the shareholders, rather then steering in function of short term needs of the shareholders which is only good for trader and not for investors.

If a CEO does B because of the stock price while he knows he actually has to do A for the good of the company, then traders win and investors loose.